SEARCH

Search Details

Ikezazawa Yausyuki

Hokkaido University Hospital Institute of Health Science Innovation for Medical CareSpecially Appointed Assistant Professor
Institute for Integrated Innovations Institute for Vaccine Research and DevelopmentSpecially Appointed Assistant Professor

Researcher basic information

■ Degree
  • Doctor of Medicine、Doctor of Philosophy, Hokkaido University, Mar. 2014
■ URL
researchmap URLホームページURL■ Various IDs
J-Global ID■ Research Keywords and Fields
Research Keyword
  • lung cancer

Career

■ Career
Educational Background
  • Apr. 2010 - Mar. 2014, Hokkaido University, 医学研究科呼吸器内科学分野博士課程, Japan
  • Apr. 1998 - Mar. 2004, Hokkaido University, School of Medicine

Research activity information

■ Papers
  • Clinical characteristics of long-term survivors of small cell lung cancer.
    Yuki Hatakeyama; Daisuke Morinaga; Jun Sakakibara-Konishi; Riku Azuma; Kosuke Tsuji; Shotaro Ito; Tomohiko Nakamura; Yuta Takashima; Tetsuaki Shoji; Megumi Furuta; Tomohiro Goda; Hidenori Kitai; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory investigation, 64, 4, 101468, 101468, Jul. 2026, [International Magazine]
    English, Scientific journal, BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease with poor prognosis. Long-term survivors (LTS) are rare, and factors associated with LTS remain unclear. This study investigated the characteristics and treatment outcomes of LTS with SCLC. METHODS: Patients diagnosed with SCLC who received systemic therapy between 2007 and 2025 were retrospectively reviewed. LTS were defined as those surviving ≥18 months. Baseline clinical features, laboratory data, and treatment outcomes were compared between LTS and non-LTS. RESULTS: Among 217 patients, 60 were LTS. LTS were younger and had better performance status, recurrence after surgery or chemoradiotherapy, fewer liver and bone metastases, fewer metastatic organs, lower tumor burden, and lower neutrophil-to-lymphocyte ratios (NLR). In the multivariate analysis, younger age, lower tumor burden, and lower NLR were independently associated with LTS. The proportion of LTS did not differ between patients treated with or without immune checkpoint inhibitors (ICIs). LTS showed significantly longer progression-free survival (PFS) after first-line therapy and also maintained longer PFS across second- to fourth-line treatments, indicating sustained chemosensitivity. ICI-containing regimens tended to improve PFS and overall survival in both groups, though the degree of benefit varied. CONCLUSIONS: LTS with SCLC were characterized by favorable baseline features, particularly younger age, lower tumor burden, and lower NLR, as well as sustained responsiveness to later-line chemotherapy.
  • Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.
    Yutaro Nagano; Hiroshi Yokouchi; Ryota Saito; Osamu Honjo; Toshiyuki Sumi; Takayuki Kaburagi; Kenichiro Ito; Yasuyuki Ikezawa; Keiki Yokoo; Hajime Kikuchi; Sayaka Kudo; Masami Yamazoe; Ryota Shigaki; Keita Tagami; Toshiyuki Tenma; Tatsuru Ishikawa; Mamoru Takahashi; Takaaki Sasaki; Hajime Asahina; Shiro Hinotsu; Hirofumi Chiba; Satoshi Oizumi
    Cancer science, 31 May 2026, [International Magazine]
    English, Scientific journal, Non-small cell lung cancers (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations (UMs) are clinically heterogeneous, and the optimal first-line EGFR tyrosine kinase inhibitor (EGFR-TKI), as well as the role of subsequent immune checkpoint inhibitor (ICI)-based regimens, remains uncertain. We conducted a multicenter retrospective cohort study including patients with advanced or recurrent non-squamous NSCLC harboring UMs who received first-line afatinib or osimertinib between January 2015 and January 2024 at 29 hospitals in Japan, excluding exon 20 insertions and de novo T790M mutations. Inverse probability of treatment weighting adjusted baseline imbalances, and post-EGFR-TKI treatment patterns were evaluated. Among 162 patients (afatinib, n = 95; osimertinib, n = 67), weighted analyses demonstrated no significant differences in time to treatment failure (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.61-1.77) or overall survival (HR, 1.34; 95% CI, 0.73-2.44). Afatinib was associated with higher response rates and more frequent adverse events requiring dose reduction. Subgroup analyses suggested differential treatment effects according to mutation subtype, with osimertinib favoring L861X mutations and afatinib favoring compound mutations. Among 56 patients who received subsequent systemic therapy, clinical outcomes were comparable between ICI plus platinum doublet and platinum doublet alone. These findings indicate that afatinib and osimertinib provide comparable survival outcomes as first-line therapies for NSCLC with UMs, with treatment effects varying by molecular subtype, while subsequent ICI-based regimens may confer limited additional benefit.
  • Pathological and molecular characterization of a four-component combined small cell lung carcinoma: a case report.
    Yasuyuki Ikezawa; Yoshiki Shinomiya; Kanako C Hatanaka; Keishi Makita; Hiroki Nishimura; Toichiro Takagi; Yukiko Tabata; Mikio Watanabe; Satoshi Konno; Yutaka Hatanaka; Yasutaka Kawai
    Translational lung cancer research, 15, 5, 155, 155, 31 May 2026, [International Magazine]
    English, Scientific journal, BACKGROUND: Combined small cell lung carcinoma (SCLC) is a rare entity and characterized by the coexistence of SCLC and non-small cell lung cancer (NSCLC) components. We report the first known case of combined SCLC containing three distinct NSCLC components: squamous cell carcinoma, pleomorphic carcinoma, and adenocarcinoma (AD). CASE DESCRIPTION: A 70-year-old man presented with right shoulder pain and underwent right upper lobectomy with en bloc chest wall resection and lymph node dissection. Histopathological examination of the resected specimen revealed four distinct histological components within the primary tumor. Comprehensive immunohistochemistry and molecular analyses, including RNA sequencing, were performed to characterize the tumor. A TP53 mutation was shared across all components, suggesting a common clonal origin, whereas additional genetic alterations were largely component specific. Clonal phylogenetic analysis indicated divergence from a common ancestral clone, supporting a structured multilineage evolutionary process. Transcriptomic profiling demonstrated lineage-associated expression patterns, and tumor microenvironment analysis revealed increased lymphocytic infiltration in the AD and pleomorphic carcinoma components, whereas proliferative signaling pathways were enriched in the SCLC component. CONCLUSIONS: These findings highlight pronounced intratumoral molecular and immunological heterogeneity. Although combined SCLC with three NSCLC components is exceedingly rare, this case provides novel insights into lineage diversification and the clonal evolution and biological diversity of combined SCLC. Further accumulation of similar cases with integrated molecular analyses is warranted to improve understanding of this rare subtype and inform future therapeutic strategies.
  • Severe psoriasis as an immune-related adverse event after long-term atezolizumab therapy for pulmonary large-cell neuroendocrine carcinoma: A case report.
    Chisa Murayama; Yasuyuki Ikezawa; Chihiro Shiiya; Yoshitaka Oda; Masafumi Ikezawa; Akihiro Matsunaga; Kosuke Tsuji; Tetsuaki Shoji; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Jun Sakakibara-Konishi; Satoshi Konno
    Respiratory medicine case reports, 61, 102421, 102421, 2026, [International Magazine]
    English, Scientific journal, Immune checkpoint inhibitors, such as atezolizumab, have become integral to the treatment of various malignancies and have significantly improved clinical outcomes by enhancing host antitumor immune responses. However, with their expanding clinical use, immune-related adverse events (irAEs) have been increasingly recognized. These events may involve any organ system and pose new challenges in patient management. Most irAEs occur within the first few months following treatment initiation; however, they may also develop unexpectedly after prolonged periods of stable therapy. Late-onset irAEs are generally mild to moderate in severity, although a subset can progress to severe forms. Dermatological toxicities are the most frequently observed irAEs. Although most cutaneous reactions are mild and manageable, severe skin toxicities, although relatively uncommon, can substantially impair patients' quality of life and may necessitate treatment modification or discontinuation. Psoriasis is a recognized cutaneous irAE that may present either as a de novo disease in patients without a history of psoriasis or as an exacerbation of pre-existing psoriasis. This case report describes a rare presentation of severe psoriasis that developed following long-term atezolizumab therapy and improved following treatment with oral prednisolone in 61-year-old man with pulmonary large-cell neuroendocrine carcinoma.
  • Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis.
    Yuriko Ishida; Shiro Watanabe; Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Hajime Kikuchi; Yasutaka Kawai; Hirokazu Kimura; Sho Nakakubo; Kenji Hirata; Kohsuke Kudo; Satoshi Konno
    Japanese journal of radiology, 44, 1, 147, 155, Jan. 2026, [Domestic magazines]
    English, Scientific journal, PURPOSE: Interstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose (FDG) accumulation in IP with lung cancer complicated with IP and the incidence of AE. This study investigates the association between FDG accumulation in the interstitial lesions and the AE incidence in patients with lung cancer complicated with IP. MATERIALS AND METHODS: This multicenter, retrospective study included patients with lung cancer complicated with IP who received chemotherapy. All CTs at baseline and the onset of AE were centrally adjudicated. The SUVpeak and FDGscore for interstitial lesions were calculated from FDG positron emission tomography images before chemotherapy, and these values were corrected using reference uptake. To determine the association with AE risk, clinical characteristics and imaging findings were compared between patients who developed AE and those who did not. Subsequently, logistic regression analysis was performed to identify risk factors for the development of AE. RESULTS: One hundred and thirteen patients who met the eligibility criteria were enrolled from three centers. However, 9 patients with a clinical diagnosis of collagen-related interstitial pneumonia were excluded due to predominant FDG accumulation in the interstitial lesions, and 104 patients were analyzed. Of those patients, 31.7% (33/104) developed all grade AE and 18.3% (19/104) developed grade 3 or higher. There were no significant differences in patient characteristics and imaging patterns between those with and without AE. SUVpeak in the ipsilateral and contralateral interstitial lesions to the tumor and the FDGscore did not differ between those with or without AE. CONCLUSIONS: No association was observed between FDG accumulation in interstitial lesions and AE in patients with lung cancer complicated with IP. We may have to remain cautious about the risk of AE in lung cancer complicated with IP, even when FDG accumulation in interstitial lesions is high or low.
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 英典; 榊原 純; 今野 哲; 椎谷 千尋; 小田 義崇
    肺癌, 65, 7, 1093, 1094, (NPO)日本肺癌学会, Dec. 2025
    Japanese
  • Atezolizumab長期投与中に免疫関連有害事象による乾癬を呈した肺大細胞神経内分泌癌の1例
    村山 千咲; 池澤 靖元; 椎谷 千尋; 小田 義崇; 池澤 将文; 福井 独歩; 吉田 有貴子; 松永 章宏; 森永 大亮; 辻 康介; 伊藤 祥太郎; 庄司 哲明; 古田 恵; 高島 雄太; 北井 秀典; 榊原 純; 今野 哲
    肺癌, 65, 5, 671, 671, (NPO)日本肺癌学会, Nov. 2025
    Japanese
  • Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
    Daisuke Morinaga; Jun Sakakibara-Konishi; Ryohei Kamada; Masahiro Kashima; Kosuke Tsuji; Shotaro Ito; Megumi Furuta; Tetsuaki Shoji; Yuta Takashima; Hidenori Kitai; Yasuyuki Ikezawa; Hiroshi Taguchi; Tatsuya Kato; Yoshiki Shinomiya; Kanako C Hatanaka; Yutaka Hatanaka; Satoshi Konno
    Thoracic cancer, 16, 13, e70119, Jul. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: During the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP. METHODS: A retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy. RESULTS: Overall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights. CONCLUSIONS: Although this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
  • Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
    Kazunari Tateishi; Hidenori Mizugaki; Yasuyuki Ikezawa; Ryo Morita; Keiki Yokoo; Toshiyuki Sumi; Mari Aso; Hajime Kikuchi; Atsushi Nakamura; Motoki Sekikawa; Fumiaki Yoshiike; Yasuo Kitamura; Nozomu Kimura; Tsutomu Hachiya; Kyoji Tsurumi; Toshihiko Agatsuma; Furuta Megumi; Keiichi Nakamura; Daisuke Jingu; Hiroshi Yamamoto; Makoto Kosaka; Hiroshi Yokouchi
    Japanese journal of clinical oncology, 55, 3, 253, 260, 05 Mar. 2025, [International Magazine]
    English, Scientific journal, BACKGROUND: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected. METHODS: We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity. RESULTS: In total, 81 (median age: 79 years) and 19 (median age: 76 years) patients received MONO and COMB, respectively. Twenty patients with a performance status (PS) score of 2-3 were enrolled in the MONO group. The median progression-free survival (PFS) was 7.8 and 8.9 months in the MONO and COMB groups, respectively. The median overall survival (OS) was 14.6 and 20.3 months, and the 2-year survival rates were 38.8 and 49.9%, respectively. Furthermore, 29.6% and 26.3% of patients discontinued treatment due to adverse events, respectively. In MONO, patients with PS 0-1 had a longer PFS (10.5 months) and OS (21.7 months) than those with PS 2-3 (0.7 and 1.6 months, respectively). CONCLUSION: Some elderly patients with NSCLC and high PD-L1 expression might benefit from COMB; however, MONO is considered the preferred treatment. MONO may not be an effective or feasible treatment for patients with PS 2-3, even with high PD-L1 expression.
  • Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan.
    Osamu Taniguchi; Yoshitaka Saito; Yuka Yamaguchi; Midori Sakai; Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Mina Eguchi; Yoh Takekuma; Mitsuru Sugawara
    Case reports in oncology, 18, 1, 151, 158, 2025, [International Magazine]
    English, Scientific journal, INTRODUCTION: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. CASE PRESENTATION: A man in his 70s was diagnosed with stage IIIA lung adenocarcinoma and received CBDCA and nab-PTX as the first-line treatment. The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital's adopted medication. During the first treatment cycle, his serum creatinine levels increased from 1.0 to 1.5 mg/dL, suggesting CBDCA-associated renal impairment. Because of gastric discomfort on day 15 of the second cycle, lansoprazole was switched to vonoprazan 10 mg once daily. On day 23 of the second cycle, he developed torsades de pointes and was hospitalized; severe hypomagnesemia (0.4 mg/dL) was detected to be causing the symptoms. Discontinuation of vonoprazan and a single intravenous infusion of 60 mEq magnesium sulfate raised serum magnesium levels to 3.7 mg/dL, and the arrhythmia disappeared. Mild hypomagnesemia (1.4 mg/dL) reappeared 5 days later, and an additional intravenous infusion of 20 mEq magnesium sulfate with subsequent oral magnesium oxide (1,980 mg/day) resolved the symptoms. CBDCA was discontinued and nab-PTX monotherapy was continued. Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ≥2 hypomagnesemia did not reappear later. CONCLUSIONS: This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.
  • Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer.
    Jun Sakakibara-Konishi; Hirofumi Takahashi; Kenichiro Ito; Tomoo Ikari; Yasuyuki Ikezawa; Hidenori Kitai; Megumi Furuta; Yuta Takashima; Tetsuaki Shoji; Masahide Fukudo; Satoshi Konno
    Respiratory medicine case reports, 53, 102176, 102176, 2025, [International Magazine]
    English, Scientific journal, Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1-2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes. Selpercatinib is a highly effective RET inhibitor for RET-rearranged patients with NSCLC and shows mostly tolerable adverse events. However, hypertension, aspartate aminotransferase increase, and alanine aminotransferase increase are the most common adverse events, and dose modification or discontinuation is required occasionally. Here, we describe a case who has response to 40 mg of selpercatinib every other day because the dose had to be adjusted owing to adverse events such as liver dysfunction. Dose modification of selpercatinib, according to adverse event incidences, may be considered, as selpercatinib may be effective in some cases even at very low concentrations.
  • Efficacy and safety of lenvatinib in a case of thymic carcinoma complicated with interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report.
    Yuki Hatakeyama; Jun Sakakibara-Konishi; Masato Tarumi; Kosuke Tsuji; Hirofumi Takahashi; Megumi Furuta; Yuta Takashima; Hidenori Kitai; Tetsuaki Shoji; Yasuyuki Ikezawa; Satoshi Konno
    Respiratory medicine case reports, 54, 102181, 102181, 2025, [International Magazine]
    English, Scientific journal, Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD. In August 2016, the patient developed ILD with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM). She received triple therapy comprising prednisolone, tacrolimus and azathioprine. In October 2021, the patient complained of lateral chest pain and back pain. In January 2022, computed tomography (CT) revealed an anterior mediastinal tumor, and percutaneous biopsy resulted in a diagnosis of thymic carcinoma with Masaoka classification IVb. In March 2022, first-line treatment with four cycles of carboplatin (area under the curve, 6) + paclitaxel (200 mg/m2) was initiated. Although a partial response was achieved, in September 2022, CT demonstrated progressive disease (PD). Therefore, in October 2022, Lenvatinib (24 mg) was started as the second-line treatment. The best response was stable disease; moreover, although lenvatinib dose reduction was required owing to adverse events, such as biliary-tract infection and stomatitis. The patient did not experience ILD exacerbation. Lenvatinib (14 mg) was continued until PD was observed in March 2023. Our findings suggest that lenvatinib is a viable treatment option for thymic carcinoma with ILD.
  • Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
    Yasuyuki Ikezawa; Ryo Morita; Hidenori Mizugaki; Kazunari Tateishi; Keiki Yokoo; Toshiyuki Sumi; Hajime Kikuchi; Yasuo Kitamura; Atsushi Nakamura; Maki Kobayashi; Mari Aso; Nozomu Kimura; Fumiaki Yoshiike; Furuta Megumi; Hisashi Tanaka; Motoki Sekikawa; Tsutomu Hachiya; Keiichi Nakamura; Fumihiro Hommura; Noriaki Sukoh; Kenichiro Ito; Takashi Kikuchi; Toshihiko Agatsuma; Hiroshi Yokouchi
    Cancer medicine, 13, 14, e70036, Jul. 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD-L1 expression who received MONO or COMB as a first-line treatment. Here, we report updated data and evaluate the long-term outcomes. METHODS: We performed a retrospective multicenter study of 298 patients with NSCLC and high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff. RESULTS: In total, 164 (median age: 74 years) and 134 (median age: 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0-1). At the prolonged data cutoff, the median follow-up was 20.2 (range: 0.1-41.4) months. The median progression-free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow-up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO. CONCLUSIONS: COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.
  • A case of lung squamous cell carcinoma with marked collapsed change after immuno-chemotherapy
    若林健人; 中里信一; 大川紘弥; 加藤憲士郎; 宮石陸; 池澤靖元; 榊原純; 加藤達哉; 外丸詩野; 松野吉宏
    日本病理学会会誌, 113, 1, 360, 360, (一社)日本病理学会, Feb. 2024
    Japanese
  • 抗血小板薬・抗凝固薬内服患者における経気管支生検の有害事象の検討
    庄司 哲明; 品川 尚文; 高島 雄太; 菊池 創; 池澤 靖元; 高階 太一; 今野 哲
    気管支学, 45, 2, 89, 97, (NPO)日本呼吸器内視鏡学会, Mar. 2023
    Japanese
  • Current status of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001).
    Ikezawa Y; Mizugaki H; Morita R; Tateishi K; Yokoo K; Sumi T; Kikuchi H; Kitamura Y; Nakamura A; Kobayashi M; Aso M; Kimura N; Yoshiike F; Furuta M; Tanaka H; Sekikawa M; Hachiya T; Nakamura K; Shimokawa M; Oizumi S
    Cancer Science, 113, 2109, 2117, 2022, [Peer-reviewed], [Lead author]
  • First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002).
    Gaku Yamamoto; Hajime Asahina; Osamu Honjo; Toshiyuki Sumi; Atsushi Nakamura; Kenichiro Ito; Hajime Kikuchi; Fumihiro Hommura; Ryoichi Honda; Keiki Yokoo; Yuka Fujita; Satoshi Oizumi; Ryo Morita; Yasuyuki Ikezawa; Hisashi Tanaka; Nozomu Kimura; Takaaki Sasaki; Noriaki Sukoh; Taichi Takashina; Toshiyuki Harada; Hirotoshi Dosaka-Akita; Hiroshi Isobe
    Scientific reports, 11, 1, 23140, 23140, 30 Nov. 2021, [International Magazine]
    English, Scientific journal, Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for elderly patients aged 75 years or older. To assess the potential clinical benefits of osimertinib in this population, this retrospective multi-institutional observational study included 132 patients with non-small cell lung cancer (age ≥ 75 years), who received osimertinib as first-line treatment. The proportion of patients with 1-year progression-free survival was 65.8% (95% confidence interval 57.1-73.5). The median progression-free survival was 19.4 (95% confidence interval 15.9-23.9) months. The median overall survival was not reached (95% confidence interval 24.6-not reached). The frequency of pneumonitis was 17.4%, with a grade 3 or higher rate of 9.1%. More than two-thirds of treatment discontinuations due to pneumonitis occurred within 3 months of starting osimertinib, and the prognosis of patients with pneumonitis was unsatisfactory. Osimertinib is one of the effective first-line therapeutic options for patients aged 75 years or older; however, special caution should be exercised due to the potential development of pneumonitis.
  • 高齢者EGFR遺伝子変異陽性非小細胞肺癌に対するオシメルチニブ初回治療の検討(HOT2002)
    本庄統; 山本岳; 朝比奈肇; 角俊行; 中村敦; 伊藤健一郎; 菊池創; 本村文宏; 本田亮一; 横尾慶紀; 藤田結花; 大泉聡史; 守田亮; 池澤靖元; 田中寿志; 木村望; 佐々木高明; 須甲憲明; 秋田弘俊; 磯部宏
    日本肺癌学会学術集会号(CD-ROM), 62nd, 6, 566, 566, (NPO)日本肺癌学会, Oct. 2021
    Japanese
  • A Case of Pulmonary Pleomorphic Carcinoma with an Epidermal Growth Factor Receptor Gene Exon 20 Insertion Mutation Treated with Osimertinib
    Sato Yuma; Kawai Yasutaka; Ichinohe Arika; Kiuchi Takayuki; Ikezawa Yasuyuki
    Haigan, 61, 5, 412, 416, The Japan Lung Cancer Society, Oct. 2021
    Japanese, Background. The positivity rate of epidermal growth factor receptor (EGFR) gene mutations in pulmonary pleomorphic carcinoma (PPC) is approximately 15-20%. Most EGFR gene mutations in PPC are common mutations. Cases of EGFR exon 20 insertion mutation positivity are very rare. Case. A 62-year-old man was referred to our hospital because of hemoptysis related to a lung tumor. Computed tomography revealed a lung tumor shadow with a cavity in the left lower lobe. Thoracoscopic left lower lobectomy was performed, and a diagnosis of PPC pT3N0M0 Stage IIB was confirmed. The patient presented with low back pain and right femoral pain, bone metastasis of the first lumbar vertebra and right femoral trochanter, lung metastasis, left renal metastasis, and left cerebral metastasis, and a diagnosis of recurrence was made. A gene mutation search was performed on the surgical specimen, and a positive test for the EGFR exon 20 insertion mutation was obtained. After mild irradiation of the first lumbar vertebral metastasis and intramedullary nail placement for the right femoral metastasis, osimertinib (80 mg/day) was administered. One month after treatment, the lung metastasis was reduced, and osteolytic changes improved in the first lumbar vertebra. However, three months after treatment, the left renal and left cerebral metastases had increased. We therefore concluded that the disease had progressed. Conclusion. Although no long-term response was obtained, we encountered a rare case in which treatment with osimertinib was administered in the early perioperative period for EGFR exon 20 insertion mutation-positive PPC, and a certain degree of disease control was achieved.
  • Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report.
    Michiko Takimoto Sato; Yasuyuki Ikezawa; Mineyoshi Sato; Akira Suzuki; Yasutaka Kawai
    Molecular and clinical oncology, 13, 1, 43, 47, Jul. 2020, [International Magazine]
    English, Scientific journal, Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare type of lung cancer, accounting for 3% of all lung cancers. The prognosis is poor and the standard therapy has not been well established. Herein, we report a case of advanced LCNEC of the lung that responded to nivolumab. The patient was a 62-year old man with stage IVB LCNEC of the lung. The disease progressed following the administration of second-line chemotherapy, and he was treated with nivolumab 3 mg/kg as the third-line treatment. Although treatment was ceased after two cycles due to interstitial pneumonia, the disease remained stable for approximately six months under observation. There was no other adverse event related to nivolumab. Following patient mortality from tumor progression, PD-L1 expression was observed to be negative (tumor proportion score <1%) by a re-examination of the primary biopsy specimen. The case herein suggests that nivolumab may be a possible treatment option for LCNEC.
  • 肺炎を繰り返した後、頻回の喀血を呈した高度肺気腫の1例
    合田 大樹; 池澤 靖元; 有里 仁希; 嘉島 相裕; 河井 康孝; 木内 隆之; 大塚 紀幸
    王子総合病院医学雑誌, 10, 73, 76, (医)王子総合病院, Jul. 2020
    Japanese
  • ロルラチニブ治療後にクリゾチニブ再投与が著効したALK融合遺伝子陽性肺腺癌の1例
    辻 康介; 榊原 純; 北井 秀典; 水柿 秀紀; 朝比奈 肇; 菊地 順子; 菊地 英毅; 品川 尚文; 今野 哲; 池澤 靖元; 畑中 豊; 佐々木 高明; 吉田 遼平; 千葉 伸一; 松本 慎吾; 後藤 功一
    肺癌, 59, 7, 1200, 1200, (NPO)日本肺癌学会, Dec. 2019
    Japanese
  • Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Jun Sakakibara-Konishi; Hidenori Kitai; Yasuyuki Ikezawa; Yutaka Hatanaka; Takaaki Sasaki; Ryohei Yoshida; Shinichi Chiba; Shingo Matsumoto; Koichi Goto; Hidenori Mizugaki; Naofumi Shinagawa
    Clinical lung cancer, 20, 5, e555-e559, Sep. 2019, [International Magazine]
    English, Scientific journal
  • A Case of Severe Mediastinitis, Pericarditis and Sepsis After Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
    池澤靖元; 森永大亮; 伊藤祥太郎; 瀧本理子; 瀧本理子; 佐藤峰嘉; 佐藤峰嘉; 河井康孝; 渡邊雅弘; 横内浩
    気管支学, 41, 3, 250, 256, The Japan Society for Respiratory Endoscopy, 2019, [Peer-reviewed], [Lead author]
    Japanese, Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is now widely performed for sampling mediastinal lymph nodes to aide in diagnosis, although complications associated with the procedure have been reported. Some infectious complications, such as mediastinitis and pneumonia, are rare, while pericarditis is extremely rare. Case. A 69-year-old presenting with bloody sputum had visited a hospital to which he had been introduced, where chest computed tomography (CT) revealed an abnormal shadow. He underwent EBUS-TBNA for diagnosis and staging and was given antibiotics prophylactically. Subsequently, the patient was diagnosed with adenocarcinoma of the lung and referred to our department for chemotherapy. The patient had a slight fever, general malaise, and dyspnea 1 week before admission. When he was admitted for chemotherapy 25 days after the EBUS-TBNA, CT revealed slightly enlarged mediastinal lymph nodes, and further swelling of subcarinal lymph nodes, which were punctured by EBUS-TBNA and had a more enlarged low-density area, and pericardial effusion. Then, the patient was given a diagnosis of mediastinitis, pericarditis, and sepsis. The patient's general condition gradually improved with pericardial drainage and antibiotic treatment. Pericardial effusion fluid cultures revealed the presence of Streptococcus viridans, and blood cultures revealed the presence of Prevotella melaninogenica. Conclusions. Because early diagnosis and treatment of pericarditis can rescue the patient, we should examine immediately when critical complications, such as pericarditis, associated with EBUS-TBNA are suspected.
  • 肺癌に合併した静脈血栓塞栓症の治療中に発症したTrousseau症候群の一例
    長島 諒太; 池澤 靖元; 瀧本 理子; 佐藤 峰嘉; 河井 康孝
    王子総合病院医学雑誌, 8, 25, 28, (医)王子総合病院, Jul. 2018
    Japanese
  • Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
    Tetsuaki Shoji; Hidenori Mizugaki; Yasuyuki Ikezawa; Megumi Furuta; Yuta Takashima; Hajime Kikuchi; Houman Goudarzi; Hajime Asahina; Junko Kikuchi; Eiki Kikuchi; Jun Sakakibara-Konishi; Naofumi Shinagawa; Ichizo Tsujino; Masaharu Nishimura
    Internal medicine (Tokyo, Japan), 57, 12, 1769, 1772, 15 Jun. 2018, [Domestic magazines]
    English, Scientific journal, This report describes the case of a 66-year-old man with non-small cell lung cancer and venous thromboembolism (VTE). Unfractionated heparin (UFH) was initially used to control VTE before chemotherapy. However, switching UFH to warfarin or edoxaban, a novel oral anticoagulant (NOAC), failed. Chemotherapy was then administered to control the tumor which was thought to have been the main cause of VTE, which had been treated by UFH. After tumor shrinkage was achieved by chemotherapy, we were able to successfully switch from UFH to edoxaban. Controlling the tumor size and activity enabled the use of edoxaban as maintenance therapy for VTE.
  • Combined antitumor effect of gamma-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer
    Jun Sakakibara-Konishi; Yasuyuki Ikezawa; Satoshi Oizumi; Junko Kikuchi; Eiki Kikuchi; Hidenori Mizugaki; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22, 2, 257, 268, Apr. 2017, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal
  • Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.
    Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Hidenori Mizugaki; Satoshi Oizumi; Masaharu Nishimura
    International journal of clinical oncology, 22, 1, 59, 69, Feb. 2017, [Domestic magazines]
    English, Scientific journal, BACKGROUND: The Notch receptor plays an important role in various cell fate decisions during development and in cancer. We have previously reported that Notch3 is upregulated by radiation in non-small cell lung cancer (NSCLC) cell lines and that the Notch pathway inhibitor γ secretase inhibitor GSI (gamma-secretase inhibitor), when combined with radiation therapy, significantly suppressed the growth of lung cancer cells. However, little is known about the mechanism of Notch upregulation induced by radiation. Based on reports of Notch expression being activated through the hypoxia inducible factor 1 (HIF-1) under hypoxic conditions, we hypothesized that HIF-1 would be involved in radiation-induced Notch activation in NSCLC. METHODS: Changes in HIF-1 and Notch expression in two Notch expressing NSCLC cells line after radiation treatment were examined using Western blotting. Notch expression was evaluated after the suppression of HIF-1α by small interfering RNA. The cytotoxic effect of YC-1, a HIF inhibitor, GSI and radiation was examined using the MTT assay in vitro and the xenograft model. RESULT: We found radiation-induced expression of HIF-1α protein at 2-6 h after treatment and upregulated expression of Notch3 protein at 24 h after treatment under hypoxic conditions. Specific suppression of HIF-1α expression downregulated the radiation-induced Notch3 activation, suggesting that the Notch pathway is activated though HIF-1α after radiation. An antitumor effect of YC-1 was evident under hypoxic conditions only when there was simultaneous radiation treatment. GSI and YC-1 had a synergistic antitumor effect in vitro, and the combination of GSI and YC-1 showed the greatest radiosensitivity in vivo. CONCLUSION: Radiation-induced upregulation of the Notch pathway and HIF-1α protein may be potential therapeutic targets for more effective radiation therapy.
  • Usefulness of Endobronchial Ultrasonography With a Guide Sheath and Virtual Bronchoscopic Navigation for Ground-Glass Opacity Lesions.
    Yasuyuki Ikezawa; Naofumi Shinagawa; Noriaki Sukoh; Megumi Morimoto; Hajime Kikuchi; Masahiro Watanabe; Kosuke Nakano; Satoshi Oizumi; Masaharu Nishimura
    The Annals of thoracic surgery, 103, 2, 470, 475, Feb. 2017, [International Magazine]
    English, Scientific journal, BACKGROUND: Endobronchial ultrasonography with guide sheath (EBUS-GS) could be useful for diagnosing ground-glass opacity (GGO) predominant-type lesions in the peripheral lung. Furthermore, several studies have reported that transbronchial biopsy using EBUS-GS and virtual bronchoscopic navigation (VBN) was safe and effective for diagnosing small peripheral lung lesions. Our objectives were to diagnose solitary peripheral GGO predominant-type lesions by transbronchial biopsy using EBUS-GS and VBN under radiographic fluoroscopic guidance, and to evaluate the clinical factors associated with diagnostic yield. METHODS: The medical records of 169 patients with GGO predominant-type lesions who underwent transbronchial biopsy using EBUS-GS and VBN under radiographic fluoroscopic guidance were retrospectively reviewed. RESULTS: Endobronchial ultrasonography images could be obtained for 156 (92%) of 169 GGO predominant-type lesions, and 116 (69%) were successfully diagnosed by this method (20 of 31 pure GGO lesions [65%]; 96 of 138 mixed GGO predominant-type lesions [70%]). The mean size of diagnosed lesions was significantly larger than that of nondiagnosed lesions (22 mm versus 18 mm, p < 0.01). Regarding diagnostic yield based on computed tomography sign, cases with presence of a bronchus leading directly to a lesion had significantly higher diagnostic yield than the other lesions (p < 0.01). CONCLUSIONS: The addition of VBN to EBUS-GS could be useful in clinical practice for diagnosing GGO predominant-type lesions in the peripheral lung.
  • A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
    Ikezawa Y; Asahina H; Oizumi S; Watanabe M; Takamura K; Kawai Y; Yamada N; Harada T; Kinoshita I; Fujita Y; Miyauchi E; Ogi T; Amano T; Furuta M; Sakakibara-Konishi J; Nishihara H; Dosaka-Akita H; Isobe H; Nishimura M; on behalf of; Hokkaido Lung; Cancer Clinical; Study Group
    Cancer Chemother Pharmacol, 80, 955, 963, 2017, [Peer-reviewed]
  • Inhibition of Notch and HIF enhances the antitumor effect radiation in Notch expressing lung cancer
    International Journal of Clinical Oncology, 22, 59, 69, 2017, [Peer-reviewed], [Lead author]
  • Usefulness of EBUS-GS and virtual bronchoscopic navigation for ground glass opacity lesions
    Ikezawa Y; Shinagawa N; Sukoh N; Morimoto M; Kikuchi H; Watanabe M; Nakano K; Oizumi S; Nishimura M
    The Annals of Thoracic Surgery, 103, 470, 475, 2017, [Peer-reviewed], [Lead author]
  • 指尖転移を来した肺扁平上皮癌の1例
    池澤靖元; 水柿秀紀; 岡田宏美; 大泉聡史; 松野吉弘; 西村正治
    日本呼吸器学会誌, 5, 189, 193, 2016, [Peer-reviewed]
  • 静脈血栓塞栓症合併肺癌症例の血栓治療に関する検討
    池澤靖元; 榊原純; 庄司哲明; 高島雄太; 森本恵; 菊池創; 高階太一; 大泉聡史; 辻野一三; 西村正治
    肺癌, 55, 1001, 1007, 2015, [Lead author]
  • Endobronchial ultrasonography with a guide sheath for pure or mixed ground-glass opacity lesions.
    Yasuyuki Ikezawa; Noriaki Sukoh; Naofumi Shinagawa; Kosuke Nakano; Satoshi Oizumi; Masaharu Nishimura
    Respiration; international review of thoracic diseases, 88, 2, 137, 43, 2014, [International Magazine]
    English, Scientific journal, BACKGROUND: Ground-glass opacity (GGO) lesions are difficult to diagnose by transbronchial biopsy (TBB). OBJECTIVES: We attempted to diagnose solitary peripheral GGO predominant-type lesions by TBB using endobronchial ultrasonography with a guide sheath (EBUS-GS) under X-ray fluoroscopic guidance, and to evaluate several factors associated with diagnostic yield. METHODS: The medical records of 67 patients with GGO predominant-type lesions who underwent TBB using EBUS-GS under X-ray fluoroscopic guidance were retrospectively reviewed. RESULTS: Of the 67 lesions, 38 (57%) were successfully diagnosed by EBUS-GS (5/11 pure GGO lesions and 33/56 mixed GGO lesions). The diagnosable lesions were significantly larger than the nondiagnosable lesions (24 vs. 17 mm, respectively; p < 0.01). Regarding the diagnostic yield by signs on computed tomography, the lesions with a bronchus leading directly to a lesion had a significantly higher diagnostic yield than the others (p < 0.05). When GGO lesions were confirmed under X-ray fluoroscopic guidance, the diagnostic yield was 79% (vs. 40% in lesions not visible on X-ray fluoroscopy; p < 0.05). CONCLUSIONS: EBUS-GS is a useful and valuable diagnostic modality, even for GGO predominant-type lesions located at the lung periphery.
  • 当院における悪性胸膜中皮腫27例の検討
    菊池 創; 朝比奈 肇; 北井 秀典; 池澤 靖元; 高階 太一; 品川 尚文; 榊原 純; 大泉 聡史; 西村 正治; 樋田 泰浩; 加賀 基知三; 井上 哲也; 加藤 徳雄
    肺癌, 53, 7, 918, 918, (NPO)日本肺癌学会, Dec. 2013, [Peer-reviewed]
    Japanese
  • γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
    Mizugaki H.; Sakakibara-Konishi J.; Ikezawa Y.; Kikuchi J.; Kikuchi E.; Oizumi S.; Dang T. P.; Nishimura M.
    British Journal of Cancer, 106, 12, 1953, 1959, Cancer Research UK, 05 Jun. 2012
    English, BACKGROUND: Notch receptor has an important role in both development and cancer. We previously reported that inhibition of the Notch3 by γ-secretase inhibitor (GSI) induces apoptosis and suppresses tumour proliferation in non-small-cell lung cancer. Although radiation is reported to induce Notch activation, little is known about the relationship between radiation and Notch pathway. METHODS: We examined the effect of combining GSI and radiation at different dosing in three Notch expressing lung cancer cell lines. The cytotoxic effect of GSI and radiation was evaluated using MTT assay and clonogenic assay in vitro and xenograft models. Expressions of Notch pathway, mitogen-activated protein kinase (MAPK) pathway and Bcl-2 family proteins were investigated using western blot analysis. RESULTS: We discovered that the antitumour effect of combining GSI and radiation was dependent on treatment schedule. γ-Secretase inhibitor administration after radiation had the greatest growth inhibition of lung cancer in vitro and in vivo. We showed that the combination induced apoptosis of lung cancer cell lines through the regulation of MAPK and Bcl-2 family proteins. Furthermore, activation of Notch after radiation was ameliorated by GSI administration, suggesting that treatment with GSI prevents Notch-induced radiation resistance. CONCLUSION: Notch has an important role in lung cancer. Treatment with GSI after radiation can significantly enhance radiation-mediated tumour cytotoxicity.
  • [A case of thoracic empyema caused by Actinomyces species nova].
    Yasuyuki Ikezawa; Toshiyuki Harada; Yasushi Akiyama; Hideki Ogasawara; Fujiya Kishi
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 47, 8, 727, 30, Aug. 2009, [Domestic magazines]
    Japanese, Scientific journal, A 50-year-old man was referred and admitted to our hospital because of pneumonia and pleuritis. The patient had attempted suicide by inhaling automobile exhaust 3 years ago. Carbon monoxide intoxication had caused persistent disturbance of consciousness and quadriplegia. He had been tracheostomised and under nutrition by percutaneous endoscopic gastrostomy. On admission the presence of left pleural fluid with thickening of the pleura was shown on computed tomography. Thoracocentesis produced suppurative fluid with Actinomyces species nova identified by the 16S rRNA method. The patient was successfully treated with antibiotics and drainage of suppurative fluid.
  • Actinomyces 属の新菌種による膿胸の1 例.
    池澤靖元; 原田敏之; 秋山也寸史; 小笠原英紀; 岸不盡彌
    日本呼吸器学会誌, 47, 727, 730, 2009, [Peer-reviewed], [Lead author]
■ Other Activities and Achievements
■ Books and other publications
  • 呼吸器ジャーナル,若手医師のための呼吸器診療スキルアップ
    池澤靖元; 品川尚文, 気管支鏡検査(244-250頁)
    2017
■ Syllabus
  • 医学総論, 2024年, 博士後期課程, 医学院
■ Affiliated academic society
  • 日本呼吸器内視鏡学会
  • 日本呼吸器学会
  • 肺癌学会
  • 日本内科学会